Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer
- Determine bone mineral density (BMD) in patients with clinically significant early
stage prostate cancer.
- Determine whether patients who have a higher level of BMD and have had a radical
prostatectomy for cure are less likely to have an early relapse (i.e., less than 3
years) than those patients with a low level of BMD.
OUTLINE: This is a case-controlled study followed by a prospective, longitudinal, cohort
Patients undergo bone mineral density (BMD) measurements by dual-energy x-ray absorptiometry
with a densitometer. Posteroanterior measurements of the total hip are also recorded.
Patients also undergo blood collection to examine markers that provide evidence of systemic
Patients are followed every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Observational Model: Case Control, Time Perspective: Prospective
Bone mineral density
DXA scan will be done after patient signs consent and eligibilty is confirmed
Stephen W. Marcella, MD, MPH
Cancer Institute of New Jersey
United States: Federal Government
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School||New Brunswick, New Jersey 08903|